Open Label, Repeat Dose Study Evaluating YCT-529 in Healthy Males

"In the Phase 1b portion of the study (Part 1), 4 dosing cohorts and one optional 5th cohort with 4 participants in each cohort will be evaluated (approximately 20 participants): 15, 30, 90 and 180 mg.~In the Phase 1b portion of the study (Part 2), 4 dosing cohorts with 4 participants in each cohort will be evaluated (approximately 16 participant): dose to range from 30 mg upto 180 mg.~In the Phase 2a portion of the study (Part 3), up to 3 cohorts of up to 10 participants (approximately 30 participants) will receive doses within the range of doses that was well tolerated and had biological activity in the Phase 1b portion."